EICHOR

Recruiting studies: Relapsed Refractory Hematological Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
EARLY_Phase 1 · 1 location(s) · Affiliated Hospital of Nantong University · NCT06756321 A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Phase 1 · 4 location(s) · NovaOnco Therapeutics Co., Ltd. · NCT06820268 Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT05713214 A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Phase 1 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07173595 A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Phase 1 · 6 location(s) · Ascentage Pharma Group Inc. · NCT07424833 Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839 International Leukemia Target Board
Phase N/A · 7 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05270096 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Phase 1 · 8 location(s) · FBD Biologics Limited · NCT05892718 CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06735495 A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06066203 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092451 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 45 location(s) · Kura Oncology, Inc. · NCT06001788 Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
Phase 1 · 1 location(s) · CytoMed Therapeutics Pte Ltd · NCT05302037 SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07153068 Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825 Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664 B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887 CD4CAR for CD4+ Leukemia and Lymphoma
Phase 1 · 6 location(s) · Huda Salman · NCT03829540 Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Phase 1 · 11 location(s) · Vanda Pharmaceuticals · NCT03838926 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/Phase 2 · 9 location(s) · Vironexis Biotherapeutics Inc. · NCT06533579 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572 A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Phase 1 · 8 location(s) · Janssen Research & Development, LLC · NCT07572006 MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880 A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Phase 1 · 1 location(s) · Sinocelltech Ltd. · NCT06252298 Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Phase 1 · 5 location(s) · Vincerx Pharma, Inc. · NCT06034275 SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplas
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT03113643 Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R
Phase 2 · 9 location(s) · National Cancer Institute (NCI) · NCT07003295 A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NA · 1 location(s) · Shanxi Bethune Hospital · NCT06783816 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866 A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06914037

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →